# US 2020/0188428 A9 · Substances Containing AuCs and Preparation Method and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0188428 A9
- Document ID: US20200188428A9
- Status: Published application
- Kind: A9
- Application number: 16/129,884
- Filed: 2018-09-13
- Published: 2020-06-18
- Earliest claimed: 2016-08-05
- Assignees: Shenzhen Profound-View Pharma Tech Co., Ltd
- Applicants: Shenzhen Profound-View Pharma Tech Co., Ltd
- Inventors: Taolei SUN
- Web page: https://patentgrep.com/patent/US20200188428A9

## CPC

- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 9/5192: {Processes}
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/242: Gold; Compounds thereof
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- B22F 1/00: Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- C01G 7/003: {Preparation involving a liquid-liquid extraction, an adsorption or an ion-exchange}
- C12N 9/6472: {Cysteine endopeptidases (3.4.22)}
- C22C 5/02: Alloys based on gold
- G01N 33/533: with fluorescent label
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/1682: {Processes}
- B22F 1/054: Nanosized particles
- B22F 1/0545: Dispersions or suspensions of nanosized particles
- B22F 1/145: Chemical treatment, e.g. passivation or decarburisation
- B22F 1/148: Agglomerating
- B22F 9/24: starting from liquid metal compounds, e.g. solutions
- B22F 2999/00: Aspects linked to processes or compositions used in powder metallurgy
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C01P 2004/64: Nanometer sized, i.e. from 1-100 nanometer
- C01P 2004/90: Other morphology not specified above
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B22F: WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER (making alloys by powder metallurgy C22C); APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- C01G: COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts or peroxyacids C01B15/00; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium, or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds containing nitrogen, other non-metals and metal C01B21/082}; metal amides C01B21/092; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanamide C01C3/16; thiocyanates C01C3/20)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C22C: ALLOYS (treatment of alloys C21D, C22F)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS

## Abstract

Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of Aβ and α-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.

## Claims

### Claim 1

A pharmaceutical composition for preventing or treating Alzheimer's disease in a subject, said pharmaceutical composition comprising a substance containing gold clusters (AuCs); wherein said substance comprises:
AuCs; and
a ligand Y coating the AuCs externally, and
a pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the AuCs has a gold core diameter smaller than 3 nm.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the ligand Y is one selected from the group consisting of L(D)-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the L(D)-cysteine and its derivatives are L(D)-cysteine, N-isobutyryl-L(D)-cysteine (L(D)-NIBC), or N-acetyl-L(D)-cysteine (L(D)-NAC).

### Claim 5 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the cysteine-containing oligopeptides and their derivatives are preferably cysteine-containing dipeptides, cysteine-containing tripeptides or cysteine-containing tetrapeptides.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the cysteine-containing dipeptides are L cysteine-L-arginine dipeptide (CR), L-arginine-L-cysteine dipeptide (RC), L-histidine-L-cysteine dipeptide (HC), or L-cysteine-L-histidine dipeptide (CH).

### Claim 7 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the cysteine-containing tripeptides are glycine-L-cysteine-L-arginine tripeptide (GCR), L-proline-L-cysteine-L-arginine tripeptide (PCR), L-lysine-L-cysteine-L-proline tripeptide (KCP), or L-glutathione (GSH).

### Claim 8 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the cysteine-containing tetrapeptides are glycine-L-serine-L-cysteine-L-arginine tetrapeptide (GSCR) or glycine-L-cysteine-L-serine-L-arginine tetrapeptide (GCSR).

### Claim 9 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the other thiol-containing compounds are 1 [(2S)-2-methyl-3-thiol-1-oxopropyl]-L-proline, thioglycollic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine or dodecyl mercaptan, etc.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the AuCs has a gold core diameter of 0.5-2.6 nm.

### Claim 24 (depends on 23)

The pharmaceutical composition according to claim 23, wherein the ligand Y is one selected from the group consisting of L(D)-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds.

### Claim 25 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the L(D)-cysteine and its derivatives are L(D)-cysteine, N-isobutyryl-L(D)-cysteine (L(D)-NIBC), or N-acetyl-L(D)-cysteine (L(D)-NAC).

### Claim 26 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the cysteine-containing oligopeptides are cysteine-containing dipeptides, wherein the cysteine-containing dipeptides are L-cysteine-L-arginine dipeptide (CR), L-arginine-L-cysteine dipeptide (RC), L-histidine-L-cysteine dipeptide (HC), or L-cysteine-L-histidine dipeptide (CH).

### Claim 27 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the cysteine-containing oligopeptides are cysteine-containing tripeptides; wherein the cysteine-containing tripeptides are glycine-L-cysteine-L-arginine tripeptide (GCR), L-proline-L-cysteine-L-arginine tripeptide (PCR), L-lysine-L-cysteine-L-proline tripeptide (KCP), or L-glutathione (GSH).

### Claim 28 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the cysteine-containing oligopeptides are cysteine-containing tetrapeptides; wherein the cysteine-containing tetrapeptides are glycine-L-serine-L-cysteine-L-arginine tetrapeptide (GSCR) or glycine-L-cysteine-L-serine-L-arginine tetrapeptide (GCSR).

### Claim 29 (depends on 24)

The pharmaceutical composition according to claim 24, wherein the other thiol-containing compounds are 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L-proline, thioglycollic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine, or dodecyl mercaptan.

### Claim 30

A method for treating a subject with Alzheimer's disease, said method comprising:
administrating a pharmaceutical composition into the subject with Alzheimer's disease in an effective amount;
wherein said pharmaceutical composition comprising a substance containing gold clusters (AuCs); wherein said substance comprises:
AuCs;
a ligand Y coating the AuCs externally, and
a pharmaceutically acceptable recipient.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the AuCs has a gold core diameter smaller than 3 nm.

### Claim 32 (depends on 30)

The method according to claim 30, wherein the ligand Y is one selected from the group consisting of L(D)-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives, and other thiol-containing compounds.

### Claim 33 (depends on 30)

The method according to claim 30, wherein the AuCs has a gold core diameter of 0.5-2.6 nm.
